Table 2.
Characteristics of Subjects with High-Level Data Reporting
| Characteristics of Subjects | Cohort 1 (18–59 yr) | Cohort 2 (60–69 yr) | Cohort 3 (70+ yr) | P Value |
|---|---|---|---|---|
| No. of subjects | 710 | 498 | 71 | |
| Age at transplantation, median (range), yr | 53 (22–59) | 64 (60–69) | 71(70–78) | |
| Age at transplantation, yr | ||||
| 18–49 yr | 222(31) | – | <.0001 | |
| 50–59 yr | 488 (69) | – | – | |
| 60–64 yr | – | 303 (61) | – | |
| 65–69 yr | – | 195 (39) | – | |
| 70–74 yr | – | – | 64 (90) | |
| 75–79 yr | – | – | 7(10) | |
| Male sex | 408 (57) | 275 (55) | 49 (69) | .0878 |
| Region | ||||
| United States | 693 (98) | 484 (97) | 70 (99) | .7494 |
| KPS before transplantation | ||||
| ≥80 | 394 (55) | 248 (50) | 35 (49) | .3293 |
| <80 | 281 (40) | 219 (44) | 31(44) | |
| Missing | 35(5) | 31 (6) | 5(7) | |
| HCTCI score | ||||
| 0–1 | 423 (60) | 280 (56) | 36(51) | .6178 |
| 2–3 | 195 (27) | 138(28) | 23 (32) | |
| >3 | 79(11) | 69 (14) | 11(15) | |
| Missing | 13(2) | 11 (2) | 1(1) | |
| Immunochemical subtype of plasma cell myeloma | ||||
| IgG | 410(58) | 297 (60) | 40 (56) | .7742 |
| IgA | 138(19) | 114(23) | 15(21) | |
| Light chain | 135(19) | 71 (14) | 14 (20) | |
| Others (Ig D/M/E) | 12(2) | 5(1) | 1(1) | |
| Nonsecretory | 15(2) | 11 (2) | 1(1) | |
| Serum creatinine at transplantation ≥1.5 | 70(10) | 71 (14) | 13(18) | .0245 |
| Lines of chemotherapy before transplantation | ||||
| 1 | 551 (78) | 375 (75) | 55(77) | .6394 |
| 2 | 159(22) | 123(25) | 16(23) | |
| Induction chemotherapy | ||||
| Thalidomide + bortezomib | 58(8) | 43(9) | 6(8) | .1158 |
| Lenalidomide + bortezomib | 160(23) | 79(16) | 12(17) | |
| Thalidomide-based | 116(16) | 103(21) | 20 (28) | |
| Lenalidomide-based | 175 (25) | 134(27) | 16(23) | |
| Bortezomib-based | 161 (23) | 116(23) | 14 (20) | |
| Steroids/cytoxan | 40(6) | 23(5) | 3(4) | |
| Disease status before AHCT | ||||
| CR | 114(16) | 85(17) | 12(17) | .8670 |
| VGPR | 199(28) | 143 (29) | 22(31) | |
| PR | 326 (46) | 230 (46) | 30 (42) | |
| SD | 56(8) | 32(6) | 4(6) | |
| REL/PROG | 15(2) | 8(2) | 3(4) | |
| Sensitivity to chemotherapy before transplantation | 639 (90) | 458 (92) | 64 (90) | .4992 |
| MEL, median (range), mg/m2 | 200(116–214) | 200 (137–220) | 200 (108–200) | |
| <140 mg/m2 | 5(<1) | 2(3) | 6(8) | <.0001 |
| 140–180 mg/m2 | 68(10) | 86(17) | 22(31) | |
| 180- ≥200 mg/m2 | 631 (89) | 406(82) | 43(61) | |
| Unknown | 6(<1) | 4(<1) | 0(0) | |
| Cytogenetic before transplantation | ||||
| Abnormal | 311(44) | 220 (43) | 33 (46) | .2932 |
| Normal | 294(41) | 191 (38) | 32 (45) | |
| Untested/unknown | 105(15) | 87(17) | 6(8) | |
| Time from diagnosis to transplantation, median (range), mo | 7(2–23) | 8 (3–24) | 8 (4–23) | |
| <12 mo | 605 (85) | 411(83) | 61 (86) | .5835 |
| 12–18 mo | 77(11) | 66(13) | 6(8) | |
| 19–24 mo | 28(4) | 21 (4) | 4(6) | |
| Type of transplantation | ||||
| Single | 632 (89) | 454 (91) | 70 (99) | .0249 |
| Tandem | 78(11) | 44(9) | 1(1) | |
| Year of transplantation | ||||
| 2008 | 364(51) | 252(51) | 35 (49) | .0068 |
| 2009 | 92(13) | 98 (20) | 16(23) | |
| 2010 | 102 (14) | 53(11) | 12(17) | |
| 2011 | 152(21) | 95 (19) | 8(11) | |
| In-hospital days, median (range) | 14(0–71) | 14 (0–60) | 14 (0–42) | .0012 |
| Evaluable | 597 (84) | 442 (89) | 64 (90) | |
| Median follow-up of survivors, mo | 35(3–61) | 37 (3–60) | 36(5–52) |
Follow-up completeness index: at 1 year (99%), at 3 years (90%), and at 5 years (82%).